• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

作者信息

Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, Rousseau A, Fenaux P, Chevret S, Chapuis N, Boeva V, Fridman W H, Fontenay M, Kosmider O

机构信息

Institut Cochin, Department Development, Reproduction, Cancer, Paris, France.

Institut National de la Santé et de la recherche médicale INSERM U1016, Paris, France.

出版信息

Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3.

DOI:10.1038/leu.2017.305
PMID:28972593
Abstract
摘要

相似文献

1
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.来那度胺介导的非5q缺失型骨髓增生异常综合征红系改善与骨髓免疫重塑相关。
Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3.
2
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.对伴有 del(5q)骨髓增生异常综合征患者骨髓微环境进行深度测序，揭示了免疫原性选择的痕迹，以及作为来那度胺反应模式产生新的 T 细胞簇。
Haematologica. 2019 Jul;104(7):1355-1364. doi: 10.3324/haematol.2018.208223. Epub 2019 Jan 17.
3
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.来那度胺治疗对伴有 5q 染色体缺失的骨髓增生异常综合征患者造血的影响。
Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.
4
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.体细胞突变对低危非5q缺失型骨髓增生异常综合征患者来那度胺治疗反应的影响。
Leukemia. 2021 Mar;35(3):897-900. doi: 10.1038/s41375-020-0961-3. Epub 2020 Jul 13.
5
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).来那度胺暴露对低危骨髓增生异常综合征伴del(5q)患者的反应和预后的影响。
Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z.
6
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.来那度胺在 del(5q) 骨髓增生异常综合征疗效中的多效作用机制。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
7
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.双重焦亡生物标志物可预测接受来那度胺和重组促红细胞生成素治疗的低危非5q缺失骨髓增生异常综合征的红系反应。
Haematologica. 2022 Mar 1;107(3):737-739. doi: 10.3324/haematol.2021.278855.
8
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.来那度胺对低危非5q缺失型骨髓增生异常综合征患者健康相关生活质量的影响：MDS-005研究结果
Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):136-144.e7. doi: 10.1016/j.clml.2017.12.004. Epub 2017 Dec 30.
9
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.来那度胺对伴有5号染色体长臂缺失的低危骨髓增生异常综合征影响的多变量时间依赖性比较
Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10.
10
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.来那度胺对一名伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效。
Leuk Lymphoma. 2010 Oct;51(10):1941-3. doi: 10.3109/10428194.2010.506567.

引用本文的文献

1
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.骨髓增生异常综合征患者使用或不使用红细胞生成刺激剂时来那度胺反应的决定因素：HOVON89 试验。
Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31.
2
Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.非 del(5q) 骨髓增生异常综合征中雷那度胺敏感性和耐药机制的鉴定。
Int J Mol Sci. 2020 May 8;21(9):3323. doi: 10.3390/ijms21093323.
3
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

本文引用的文献

1
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.利用基因表达估算组织浸润性免疫细胞和基质细胞群体的总体丰度。
Genome Biol. 2016 Oct 20;17(1):218. doi: 10.1186/s13059-016-1070-5.
2
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.随机 III 期研究：来那度胺对比安慰剂在 RBC 输血依赖型低危非 del(5q) 骨髓增生异常综合征患者中的应用，这些患者不适合或对红细胞生成刺激剂耐药。
J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.
3
对伴有 del(5q)骨髓增生异常综合征患者骨髓微环境进行深度测序，揭示了免疫原性选择的痕迹，以及作为来那度胺反应模式产生新的 T 细胞簇。
Haematologica. 2019 Jul;104(7):1355-1364. doi: 10.3324/haematol.2018.208223. Epub 2019 Jan 17.
Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.
来那度胺通过抑制E3泛素连接酶RNF41来稳定促红细胞生成素受体。
Cancer Res. 2016 Jun 15;76(12):3531-40. doi: 10.1158/0008-5472.CAN-15-1756. Epub 2016 Apr 6.
4
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.来那度胺治疗对无5q缺失的骨髓增生异常综合征克隆结构的影响。
Blood. 2016 Feb 11;127(6):749-60. doi: 10.1182/blood-2015-04-640128. Epub 2015 Dec 1.
5
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.来那度胺联合或不联合促红细胞生成素治疗不伴有 5q 缺失的输血依赖型低危 MDS 对红细胞生成刺激剂抵抗
Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.
6
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.来那度胺诱导del(5q)骨髓增生异常综合征中CK1α的泛素化和降解。
Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1.
7
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.来那度胺联合促红细胞生成素α治疗低危骨髓增生异常综合征患者。
Blood. 2012 Oct 25;120(17):3419-24. doi: 10.1182/blood-2012-03-415661. Epub 2012 Aug 30.
8
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation.来那度胺免疫调节逆转骨髓增生异常综合征中的T细胞耐受性。
Leukemia. 2012 Jun;26(6):1425-9. doi: 10.1038/leu.2011.359. Epub 2011 Dec 23.
9
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.一项来那度胺对比安慰剂在 RBC 输血依赖低/中-1 风险伴 5q- 骨髓增生异常综合征患者中随机 3 期研究。
Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.
10
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.免疫应答在低危 MDS 和高危 MDS 发病机制中的作用：免疫治疗的意义。
Br J Haematol. 2011 Jun;153(5):568-81. doi: 10.1111/j.1365-2141.2011.08683.x. Epub 2011 Apr 13.